Roy F Chemaly, MD, MPH, FIDSA, FACP, MD Anderson Cancer Center, Houston, TX, gives an overview of the use of presatovir in hematopoietic stem cell transplant (HSCT) recipients with respiratory syncytial virus (RSV) infection. Two Phase IIb studies were conducted to investigate the use of presatovir, an RSV fusion inhibitor, in HSCT recipients with RSV infection: one for recipients with RSV infection in the upper respiratory tract (NCT02254408), and one for recipients with RSV infection in the lower respiratory tract (NCT02254421). Presatovir treatment was found to be well-tolerated in HSCT recipients with RSV infection, however it did not significantly reduce the time-weighted average change in the nasal RSV load in either trial. Exploratory analyses suggested an antiviral effect among patients with lymphopenia. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Dr Roy F Chemaly, MD, MPH, FIDSA, FACP, has received research Grants from Gilead, Pulmotec, Janssen, Karius, Chimerix, Merck, Viracor, Takeda/Shire, and Ansun Pharmaceuticals; and has participated in advisory boards or consultancy work for ADMA Biologics, Pulmotec, Ablynx, Janssen, Merck, Takeda, ReViral, Kyorin, Chimerix, Partner Therapeutics, and Ansun Pharmaceuticals.